```
=> b reg
FILE 'REGISTRY' ENTERED AT 16:53:17 ON 19 OCT 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   18 OCT 2006  HIGHEST RN 910777-14-9
DICTIONARY FILE UPDATES:  18 OCT 2006  HIGHEST RN 910777-14-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=> d que sta l6
L4                STR
```




```
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  34

STEREO ATTRIBUTES: NONE
L6          110 SEA FILE=REGISTRY SSS FUL L4

100.0% PROCESSED  152218 ITERATIONS                    110 ANSWERS
SEARCH TIME: 00.00.10


=> b hcap
FILE 'HCAPLUS' ENTERED AT 16:53:29 ON 19 OCT 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
```

FILE COVERS 1907 - 19 Oct 2006 VOL 145 ISS 17
FILE LAST UPDATED: 18 Oct 2006 (20061018/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d bib abs hitrn fhitstr retable l21 tot

L21 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2006:796211 HCAPLUS
DN 145:211347
TI Acid addition salts of Ac-PHSCN-NH2
IN **Ternansky, Robert J.; Gladstone, Patricia L.; Mazar, Andrew P.; Allan, Amy L.**
PA **Attenuon, LLC, USA**
SO PCT Int. Appl., 54pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO2006084016	A1	20060810	2006WO-US03658	20060201

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRAI 2005US-649308P P 20050201
OS MARPAT 145:211347
AB The invention relates to acid addition salts of Ac-Pro-His-Ser-Cys-Asn-NH2 (Ac-PHSCN-NH2), including methods for their synthesis, pharmaceutical compns. containing them used to treat diseases associated with angiogenesis and aberrant vascularization, and methods of preventing degradation of Ac-PHSCN-NH2 by salt formation. Ac-PHSCN-NH2 was prepared by the solid-phase method and its stability in solution and the solid phase compared with that of its hydrochloric, methanesulfonic and nitric acid salts.
IT **262438-43-7P 904763-27-5P 904763-42-4P 904763-50-4P 904763-58-2P 904763-66-2P 904763-74-2P 904763-82-2P 904763-90-2P 904763-98-0P 904764-07-4P 904764-15-4P 904764-22-3P 904764-30-3P**
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and stability of acetylprolylhistidylserylcysteinylaspartamide salts for use in treating diseases associated with angiogenesis and aberrant vascularization)
IT **252229-85-9**

RL: PRP (Properties)
(unclaimed sequence; acid addition salts of Ac-PHSCN-NH2)

IT **262438-43-7P**
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and stability of acetylprolylhistidylserylcysteinylaspartamide salts for use in treating diseases associated with angiogenesis and aberrant vascularization)

RN 262438-43-7 HCAPLUS

CN L-Aspartamide, 1-acetyl-L-prolyl-L-histidyl-L-seryl-L-cysteinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Attenuon Llc	2004			WO2004047771 A	HCAPLUS
Damm, M	2004			US2004259801 A1	HCAPLUS
Livant, D	1998			WO---9822617 A	HCAPLUS

L21 ANSWER 2 OF 5 HCAPLUS COPYRIGHT 2006 ACS on STN

AN 2006:791029 HCAPLUS

DN 145:235787

TI Improved formulations of anti-angiogenic peptides

IN **Mazar, Andrew, P.**; Heiati, Hashem; Schrier, Jay; Li, Ming; Harris, Scott

PA **Attenuon**, LLC, USA

SO PCT Int. Appl., 37pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO2006083906	A2	20060810	2006WO-US03461	20060201
WO2006083906	A3	20061005		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRAI 2005US-648391P P 20050201

AB Described herein are compns./formulations of the Cys-containing anti-angiogenic peptide Pro-His-Ser-Cys-Asn (preferably in its capped form as Ac-PHSCN-NH2) or acid addition salts thereof or analog thereof, that

comprise at least one addnl. compound that stabilizes the peptide or analog against spontaneous tandem dimerization or higher oligomerization. Preferred formulations include an acidic buffer such as citrate, glycine as an excipient and bulking agent. Optional addnl. components of the formulation are a reducing agent, a non-thiol biocompatible anti-oxidant, a lyoprotectant (typically one or more sugars, one or more amino acids, one or more methylamine, one or more lyotropic salts, and/or one or more polyols). Also provided is an article of manufacture or kit comprising the formulation in solution or in lyophilized form. A method of inhibiting angiogenesis in a subject, comprising administering to the subject the peptide in the above formulation is also disclosed. Ac-Pro-His-Ser-Cys-Asn-NH2, TFA salt (140 mg, 0.197 mmol) was dissolved in 2 mL of water and Amberlyst A-26 (OH) resin (4.2 meq/g, 273 mg, 5.8 equiv) was added. The reaction mixture was stirred at room temperature for 5 min. The aqueous solution was decanted, the resin was washed twice with distilled water, and the combined aqueous layers were lyophilized to afford 81 mg (69%) of Ac-PHSCN-NH2 as a fluffy, white solid 94% monomer, 6% dimer. Ac-PHSCN-NH2, 50 mg/mL, was formulated in solns. that included the 50mM citrate 50 mg mannitol, and 10 mg sucrose and lyophilized. Stability of various formulations of the peptide was studied.

IT **262438-43-7P**
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(improved formulations of anti-angiogenic peptides)

IT **904763-42-4P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(improved formulations of anti-angiogenic peptides)

IT **904763-27-5P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(improved formulations of anti-angiogenic peptides)

IT **262438-43-7P**
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(improved formulations of anti-angiogenic peptides)

RN 262438-43-7 HCAPLUS

CN L-Aspartamide, 1-acetyl-L-prolyl-L-histidyl-L-seryl-L-cysteinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L21 ANSWER 3 OF 5 HCAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:610128 HCAPLUS

DN 141:157478

TI Peptides which target tumor and endothelial cells, compositions and uses thereof

IN **Allan, Amy L.; Yoon, Won Hyung; Gladstone, Patricia L.; Ternansky, Robert J.; Parry, Graham; Donate, Fernando; Mazar, Andrew**

PA **Attenuon**, Llc, USA
SO PCT Int. Appl., 117 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO2004063213	A2	20040729	2003WO-US37895	20031125
	WO2004063213	A3	20050303		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA---2506813	AA	20040729	2003CA-2506813	20031125
	AU2003298726	A1	20040810	2003AU-0298726	20031125
	US2004162239	A1	20040819	2003US-0723144	20031125
	US2005020810	A1	20050127	2003US-0722843	20031125
	EP---1569678	A2	20050907	2003EP-0796483	20031125
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR2003016550	A	20051004	2003BR-0016550	20031125
	CN---1741808	A	20060301	CN 2003-80109204	20031125
	CN---1741809	A	20060301	CN 2003-80109205	20031125
	JP2006515866	T2	20060608	2005JP-0512876	20031125
	NO2005003112	A	20050805	2005NO-0003112	20050624
PRAI	2002US-429174P	P	20021125		
	2003US-475539P	P	20030602		
	2003WO-US37895	W	20031125		

OS MARPAT 141:157478

AB The invention relates generally to peptide analogs of Ac-PHSCN-NH2 which target tumor and endothelial cells and have antitumor, antiangiogenic and antimetastatic activity and to methods for their synthesis and use in pharmaceutical compns. for treating, preventing and detecting diseases characterized by tumor growth, metastasis and angiogenesis. The peptide analogs may serve, inter alia, as carriers of radioactivity, PET-active compds., toxins, fluorescent mols. and PEG mols. Peptides R1[(NHCHR2CO)0-1(X1)0-100]m-X2-X3-X4-X5-X6-[(X7)0-1(NHCHR3CO)0-1]nNR4R5 [R1 is (un)substituted acyl, alkyl, cycloalkyl or imino, or acyl chelate; R2 is substituted alkyl; R4, R5 are (un)substituted alkyl; X1, X7 are NH(CH:CH)1-6CO, NH(CH2)1-6CO, NHCHMeCO; X2-X6 are α-amino acids which are defined; m, n are 0 or 1, with the proviso that R1 is not acetyl when R4 and R5 are H and m and n are 0] are claimed. Thus, Ac-Pro-His-Ser-Cys(Ac)-Asn-OH was prepared by the solid-phase method and coupled to doxorubicin hydrochloride to afford the conjugate.

IT **729594-60-9P**
RL: DGN (Diagnostic use); PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of peptides which target tumor and endothelial cells)

IT **262438-43-7DP**, analogs **729594-61-0P 729594-62-1P**
729594-63-2P 729594-64-3P 729594-65-4P
729594-66-5P 729594-67-6P 729594-68-7P
729594-69-8P 729594-70-1P 729594-71-2P
729594-72-3P 729594-73-4P 729594-74-5P
729594-75-6P 729594-76-7P 729594-77-8P
729594-78-9P 729594-79-0P 729594-80-3P
729594-81-4P 729594-82-5P 729594-83-6P
729594-84-7P 729594-85-8P 729594-86-9P
729594-87-0P 729594-88-1P 729594-89-2P

729594-90-5P 729594-91-6P 729594-92-7P
729594-93-8P 729594-94-9P 729594-95-0P
729594-96-1P 729594-97-2P 729594-98-3P
729594-99-4P 729595-00-0P 729595-01-1P
729595-02-2P 729595-04-4P 729595-05-5P
729595-06-6P 729595-07-7P 729595-08-8P
729595-09-9P 729595-14-6P 730960-54-0P
731003-01-3DP, Indium complexes 731003-01-3P
731003-02-4P
RL: DGN (Diagnostic use); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of peptides which target tumor and endothelial cells)

IT 729595-16-8D, resin-bound 729595-17-9
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of peptides which target tumor and endothelial cells)

IT 729594-60-9P
RL: DGN (Diagnostic use); PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of peptides which target tumor and endothelial cells)

RN 729594-60-9 HCAPLUS
CN L-Lysinamide, 1-acetyl-L-prolyl-L-histidyl-L-seryl-S-methyl-L-cysteinyl-L-asparaginylglycylglycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



L21 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:467702 HCAPLUS
DN 141:33798
TI Peptides which inhibit angiogenesis, cell migration, cell invasion and

cell proliferation, their preparation, and compositions and therapeutic uses thereof

IN **Allan, Amy L.**; **Donate, Fernando**; Hopkins, Stephanie A.; **Gladstone, Patricia L.**; **Mazar, Andrew**; O'Hare, Sean M.; **Parry, Graham**; Plunkett, Marian L.; **Ternansky, Robert J.**; **Yoon, Won Hyung**

PA **Attenuon**, LLC, USA

SO PCT Int. Appl., 88 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO2004047771	A2	20040610	2003WO-US38175	20031125
	WO2004047771	A3	20050915		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA---2507045	AA	20040610	2003CA-2507045	20031125
	AU2003297609	A1	20040618	2003AU-0297609	20031125
	US2004162239	A1	20040819	2003US-0723144	20031125
	US2005020810	A1	20050127	2003US-0722843	20031125
	BR2003016523	A	20051018	2003BR-0016523	20031125
	EP---1594521	A2	20051116	2003EP-0812058	20031125
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	CN---1741808	A	20060301	CN 2003-80109204	20031125
	CN---1741809	A	20060301	CN 2003-80109205	20031125
	JP2006514116	T2	20060427	2005JP-0510345	20031125
	NO2005003111	A	20050824	2005NO-0003111	20050624
PRAI	2002US-429174P	P	20021125		
	2003US-475539P	P	20030602		
	2003WO-US38175	W	20031125		

OS MARPAT 141:33798

AB The invention discloses peptides which inhibit angiogenesis, cell migration, cell invasion and cell proliferation, as well as methods of making the peptides, pharmaceutical compns. containing the peptides, and methods of using the peptides and pharmaceutical compns. to treat diseases associated with aberrant vascularization, e.g. cancer.

IT **701200-82-0P 701201-01-6P**
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(peptide inhibitors of angiogenesis, cell migration, cell invasion and cell proliferation, preparation, and compns. and therapeutic uses)

IT **701200-81-9P 701200-83-1P 701200-84-2P**
701200-88-6P 701200-90-0P 701200-91-1P
701200-92-2P 701200-93-3P 701200-99-9P
701201-00-5P 701201-02-7P 701201-03-8P
701201-04-9P 701201-05-0P 701201-06-1P
701201-07-2P 701201-08-3P 701201-09-4P
701201-10-7P 701201-11-8P 701201-12-9P
701201-13-0P 701201-14-1P 701201-15-2P
701201-16-3P 701201-17-4P 701201-18-5P
701201-19-6P 701201-20-9P 701201-21-0P
701201-24-3P 701201-25-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

(Uses)
(peptide inhibitors of angiogenesis, cell migration, cell invasion and cell proliferation, preparation, and compns. and therapeutic uses)

IT **262438-43-7**
RL: RCT (Reactant); RACT (Reactant or reagent)
(peptide inhibitors of angiogenesis, cell migration, cell invasion and cell proliferation, preparation, and compns. and therapeutic uses)

IT **701200-82-0P**
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(peptide inhibitors of angiogenesis, cell migration, cell invasion and cell proliferation, preparation, and compns. and therapeutic uses)

RN 701200-82-0 HCAPLUS

CN L-Aspartamide, 1-acetyl-L-prolyl-L-histidyl-L-seryl-S-[(4-methylphenyl)methyl]-L-cysteinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L21 ANSWER 5 OF 5 HCAPLUS COPYRIGHT 2006 ACS on STN

AN 2003:243058 HCAPLUS

DN 139:173332

TI Inhibition of integrin α5β1 function with a small peptide (ATN-161) plus continuous 5-FU infusion reduces colorectal liver metastases and improves survival in mice

AU Stoeltzing, Oliver; Liu, Wenbiao; Reinmuth, Niels; Fan, Fan; **Parry, Graham C.**; Parikh, Alexander A.; McCarty, Marya F.; Bucana, Corazon D.; **Mazar, Andrew P.**; Ellis, Lee M.

CS Department of Cancer Biology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, 77030-4009, USA

SO International Journal of Cancer (2003), 104(4), 496-503
CODEN: IJCNAW; ISSN: 0020-7136

PB Wiley-Liss, Inc.

DT Journal

LA English

AB Integrin α5β1 is expressed on activated endothelial cells and plays a critical role in tumor angiogenesis. We hypothesized that a novel integrin α5β1 antagonist, ATN-161, would inhibit angiogenesis and growth of liver metastases in a murine model. We further hypothesized that combining ATN-161 with 5-fluorouracil (5-FU) chemotherapy would enhance the antineoplastic effect. Murine colon cancer cells (CT26) were injected into spleens of BALB/c mice to produce liver metastases. Four days thereafter, mice were given either ATN-161 (100 mg/kg, every 3rd day) or saline by i.p. injection, with or without combination of continuous-infusion 5-FU (100 mg/kg/2 wk), which was started on day 7. On day 20 after tumor cell inoculation, mice were killed and liver wts. and

number of liver metastases were determined A follow-up study on survival was also conducted in which mice were randomized to receive ATN-161, 5-FU or ATN-161+5-FU. Combination therapy with ATN-161+5-FU significantly reduced tumor burden (liver weight) and number of liver metastases ($p<0.02$). Liver tumors in the ATN-161 and ATN-161+5-FU groups had significantly fewer microvessels ($p<0.05$) than tumors in the control or 5-FU-treated groups. Unlike treatment with either agent alone, ATN-161+5-FU significantly increased tumor cell apoptosis and decreased tumor cell proliferation ($p<0.03$) and improved overall survival ($p<0.03$, log-rank test). Targeting integrin $\alpha5\beta1$ in combination with 5-FU infusion reduced liver metastases formation and improved survival in this colon cancer model. The enhancement of antineoplastic activity from the combination of anti-angiogenic therapy and chemotherapy may be a promising approach for treating metastatic colorectal cancer.

IT **262438-43-7**, ATN 161
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(inhibition of integrin $\alpha5\beta1$ function with ATN-161 plus 5-FU infusion reduces colorectal liver metastases and improves survival in mice)

IT **262438-43-7**, ATN 161
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(inhibition of integrin $\alpha5\beta1$ function with ATN-161 plus 5-FU infusion reduces colorectal liver metastases and improves survival in mice)

RN 262438-43-7 HCAPLUS
CN L-Aspartamide, 1-acetyl-L-prolyl-L-histidyl-L-seryl-L-cysteinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Baker, C	2002	62	1996	Cancer Res	HCAPLUS
Bello, L	2001	61	7501	Cancer Res	HCAPLUS
Bergsland, E	2000	19	242	Proc Am Soc Clin Onc	
Braakhuis, B	1995	22	42	Semin Oncol	HCAPLUS
Brooks, P	1994	79	1157	Cell	HCAPLUS
Brooks, P	1995	96	1815	J Clin Invest	HCAPLUS
Browder, T	2000	60	1878	Cancer Res	HCAPLUS
Bruns, C	2000	89	488	Cancer	HCAPLUS
Bruns, C	2000	6	1936	Clin Cancer Res	HCAPLUS
Fidler, I	1991	10	229	Cancer Metastasis Re	MEDLINE
Friedlander, M	1995	270	1500	Science	HCAPLUS
Gately, S	2001	7	427	Cancer J	MEDLINE
Giancotti, F	1999	285	1028	Science	HCAPLUS
Gong, J	1997	8	83	Cell Growth Differ	HCAPLUS
Griggs, D	2001	42	1420	Proc Am Assoc Cancer	
Hanahan, D	2000	105	1045	J Clin Invest	HCAPLUS
Hynes, R	1992	69	11	Cell	HCAPLUS
Kakeji, Y	1997	15	39	Invest New Drugs	HCAPLUS

Kase, S	1993	13	369	Anticancer Res	HCAPLUS
Kerbel, R	2002	13	12	Ann Oncol	MEDLINE
Kerbel, R	2000	36	1248	Eur J Cancer	HCAPLUS
Kerr, J	1999	19	959	Anticancer Res	HCAPLUS
Kerr, J	2000	9	1271	Expert Opin Investig	HCAPLUS
Kim, S	2000	156	1345	Am J Pathol	HCAPLUS
Kim, S	2000	275	33920	J Biol Chem	HCAPLUS
Klement, G	2002	8	221	Clin Cancer Res	HCAPLUS
Klement, G	2000	105	R15	J Clin Invest	HCAPLUS
Klotz, O	2000	238	88	Arch Clin Exp Ophtha	HCAPLUS
Kumar, C	2000	476	169	Adv Exp Med Biol	MEDLINE
Kumar, C	2001	61	2232	Cancer Res	HCAPLUS
Livant, D	2000	60	309	Cancer Res	HCAPLUS
Lode, H	1999	96	1591	Proc Natl Acad Sci U	HCAPLUS
Morikawa, K	1990	82	517	J Natl Cancer Inst	HCAPLUS
Mross, K	2000	3	223	Drug Resist Updat	HCAPLUS
O'Brien, V	1996	224	208	Exp Cell Res	HCAPLUS
Remmenga, S	1994	55	115	Gynecol Oncol	MEDLINE
Schreiner, C	1991	9	163	Clin Exp Metastasis	HCAPLUS
Stoeltzing, O	2001	7	3656S	Clin Cancer Res	
Storgard, C	1999	103	47	J Clin Invest	HCAPLUS
Tedjarati, S	2002	8	2413	Clin Cancer Res	HCAPLUS
Varner, J	1995	6	725	Mol Biol Cell	HCAPLUS
White, E	2001	167	5362	J Immunol	HCAPLUS

=> d bib abs hitstr retable l22 tot

L22 ANSWER 1 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2006:339703 HCAPLUS
DN 144:381976
TI Anticancer compounds and methods
IN Livant, Donna
PA The Regents of the University of Michigan, USA
SO U.S. Pat. Appl. Publ., 87 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US2006078535	A1	20060413	2004US-0964093	20041013
	WO2006044330	A2	20060427	2005WO-US36442	20051011
	WO2006044330	A3	20060608		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRAI 2004US-0964093 A 20041013

AB The present invention relates to the treatment of cancer, to the testing of cancer cells for their ability to invade tissues and cause metastases, and to the identification and use of drugs to inhibit tumor invasion and growth. In one embodiment, the present invention contemplates a composition comprising a dendrimer and at least one peptide comprising an amino acid sequence PHSCN attached to said dendrimer, wherein the dendrimer comprises branches. In one embodiment, the dendrimer comprises polylysine. In one embodiment, the composition further comprises a chemotherapeutic agent attached to the dendrimer. In one embodiment, the chemotherapeutic agent comprises

methotrexate. In another embodiment, the chemotherapeutic agent comprises boron. In another embodiment, the chemotherapeutic agent comprises an antibody.

IT **252229-85-9D**, conjugates with dendrimers and chemotherapeutic agents
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(anticancer compds. and methods using dendrimers and peptides and attached chemotherapeutic agents)
RN 252229-85-9 HCAPLUS
CN L-Asparagine, L-prolyl-L-histidyl-L-seryl-L-cysteinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **252230-05-0**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(metastasis inhibition by; anticancer compds. and methods using dendrimers and peptides and attached chemotherapeutic agents)
RN 252230-05-0 HCAPLUS
CN L-Asparagine, L-prolyl-L-histidyl-L-seryl-L-homocysteinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **252229-85-9 883198-05-8 883198-06-9**
RL: PRP (Properties)
(unclaimed sequence; anticancer compds. and methods)
RN 252229-85-9 HCAPLUS
CN L-Asparagine, L-prolyl-L-histidyl-L-seryl-L-cysteinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 883198-05-8 HCAPLUS
CN L-Lysine, L-prolyl-L-histidyl-L-seryl-L-cysteinyl-L-asparaginylglycylglycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 883198-06-9 HCAPLUS
CN Glycine, L-prolyl-L-histidyl-L-seryl-L-cysteinyl-L-asparaginylglycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L22 ANSWER 2 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:1266841 HCAPLUS
DN 144:439725
TI Effect of physicochemical modification on the biodistribution and tumor accumulation of HPMA copolymers
AU Lammers, Twan; Kuehnlein, Rainer; Kissel, Maria; Subr, Vladimir; Etrych, Tomas; Pola, Robert; Pechar, Michal; Ulbrich, Karel; Storm, Gert; Huber, Peter; Peschke, Peter
CS Department of Innovative Cancer Diagnosis and Therapy, Clinical Cooperation Unit Radiotherapeutic Oncology, German Cancer Research Center, Heidelberg, 69120, Germany
SO Journal of Controlled Release (2005), 110(1), 103-118
CODEN: JCREEC; ISSN: 0168-3659
PB Elsevier B.V.
DT Journal
LA English
AB Copolymers of N-(2-hydroxypropyl)methacrylamide (HPMA) are prototypic and well-characterized polymeric drug carriers that are being broadly implemented in the delivery of anticancer therapeutics. To better predict the in vivo potential of the copolymers and to describe the biodistributional consequences of functionalization, 13 physicochem. different HPMA copolymers were synthesized, varying in mol. weight and in the nature and amount of functional groups introduced. Upon radiolabeling, the copolymers were injected i.v., and their circulation kinetics, tissue distribution and tumor accumulation were monitored in rats bearing s.c. Dunning AT1 tumors. It was found that increasing the average mol. weight of HPMA copolymers resulted in prolonged circulation times and in increased tumor concns. Conjugation of carboxyl and hydrazide groups, as well as introduction of spacer, drug and peptide moieties reduced the long-circulating properties of the copolymers and as a result, lower levels were found in tumors and in all organs other than kidney. Interestingly, however, in spite of the reduced (absolute) tumor concns., hardly any reduction in the relative levels localizing to tumors was found. Tumor-to-organ ratios were comparable to unmodified control for the majority of chemical modified copolymers, indicating that functionalization does not necessarily affect the tumor targeting ability of the copolymers and suggesting that HPMA copolymer-based drug delivery systems may prove to be attractive tools for more effectively treating various forms of advanced solid malignancy.
IT **262438-43-7D**, reaction products with hydroxypropylacrylamide polymers
RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(effect of physicochem. modification on biodistribution and tumor accumulation of HPMA copolymers)
RN 262438-43-7 HCAPLUS
CN L-Aspartamide, 1-acetyl-L-prolyl-L-histidyl-L-seryl-L-cysteinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Atkins, M	2004	10	6277S	Clin Cancer Res	
Bilim, V	2003	5	326	Curr Opin Mol Ther	HCAPLUS
Chan, W	2000			Fmoc Solid phase Pep	
Curti, B	2004	292	97	JAMA	HCAPLUS
Drobnik, J	1976	177	2833	Makromol Chem	HCAPLUS
Duncan, R	2003	2	347	Nat Rev Drug Discov	HCAPLUS
Etrych, T	2001	73	89	J Control Release	HCAPLUS
Gianasi, E	1999	35	994	Eur J Cancer	HCAPLUS
Julyan, P	1999	57	281	J Control Release	HCAPLUS
Kasuya, Y	2001	74	203	J Control Release	HCAPLUS
Kiessling, F				Submitted for public	
Kissel, M	2001	55	191	PDA J Pharm Sci Tech	HCAPLUS
Kopecek, J	2000	50	61	Eur J Pharm Biopharm	HCAPLUS
Kopecek, J	2001	74	147	J Control Release	HCAPLUS
Lin, X	2004	40	291	Eur J Cancer	HCAPLUS
Livant, D	2000	60	309	Cancer Res	HCAPLUS
Lubaroff, D	1977	58	1677	J Natl Cancer Inst	MEDLINE
Maeda, H	2000	65	271	J Control Release	HCAPLUS
Mitra, A	2004	21	1153	Pharm Res	HCAPLUS
Nishiyama, N	2003	63	7876	Cancer Res	HCAPLUS
Noguchi, Y	1998	89	307	Jpn J Cancer Res	HCAPLUS
Pouckova, P	2004	95	83	J Control Release	HCAPLUS
Rademaker-Lakhai, J	2004	10	3386	Clin Cancer Res	HCAPLUS
Reynolds, T	1995	87	1582	J Natl Cancer Inst	MEDLINE
Rihova, B	1989	10	335	Biomaterials	HCAPLUS
Rihova, B	2003	4	311	Curr Pharm Biotechno	HCAPLUS
Salacinski, P	1981	117	136	Anal Biochem	HCAPLUS
Satchi-Fainaro, R	2003	14	797	Bioconjug Chem	HCAPLUS
Satchi-Fainaro, R	2005	3	251	Cancer Cell	
Satchi-Fainaro, R	2004	10	255	Nat Med	HCAPLUS
Seymour, L	1990	39	1125	Biochem Pharmacol	HCAPLUS
Seymour, L	1995	31A	766	Eur J Cancer	HCAPLUS
Seymour, L	1987	21	1341	J Biomed Mater Res	HCAPLUS
Seymour, L	2002	20	1668	J Clin Oncol	HCAPLUS
Singal, P	1998	339	900	N Engl J Med	MEDLINE
Strohalm, J	1978	70	109	Angew Makromol Chem	HCAPLUS
Terwogt, J	2001	12	315	Anticancer Drugs	HCAPLUS
Thomson, A	1999	81	99	Br J Cancer	HCAPLUS
Ulbrich, K	2000	64	63	J Control Release	HCAPLUS
van Golen, K	2002	4	373	Neoplasia	HCAPLUS
Vasey, P	1999	5	83	Clin Cancer Res	HCAPLUS

L22 ANSWER 3 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:1259708 HCAPLUS
DN 144:19226
TI Peptide standards for quantification of human serum glycoproteins using mass spectrometry
IN Aebersold, Rudolph H.; Zhang, Hui
PA The Institute for Systems Biology, USA

SO PCT Int. Appl., 193 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO2005114221	A2	20051201	2005WO-US17842	20050520
WO2005114221	C1	20060504		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US2006141528	A1	20060629	2005US-0134871	20050520
PRAI 2004US-573593P	P	20040521		

AB The invention provides compns. and methods for identifying and/or quantifying glycopolypeptides from human serum or plasma on a proteome-wide scale. The methods can be used to determine changes in the abundance of glycoproteins and changes in the state of glycosylation at individual glycosylation sites on these glycoproteins that occur in response to perturbations of biol. systems and organisms in health and disease. The method includes the steps of derivatizing glycopolypeptides in the sample and immobilizing the derivatized sample glycopolypeptides to a solid support (hydrazine resin). The immobilized sample glycopolypeptides are then cleaved to release non-glycosylated peptide fragments and retain the immobilized sample glycopeptide fragments. The immobilized glycopeptide fragments are labeled with an isotope tag and released from the solid support, thereby generating released sample glycopeptide fragments. A plurality of standard peptides containing glycosylation site(s) are added to the released sample glycopeptide fragments, wherein the std peptides are differentially labeled with a corresponding isotope tag. The released sample glycopeptide fragments are analyzed using mass spectrometry, and those that correspond to standard peptides are identified. The compns. and methods include 3517 standard peptides containing glycosylation sites determined for human serum/plasma proteins. Differential expression of specific glycopeptide markers is demonstrated in prostate cancer tissues as compared to normal tissues.

IT **870165-03-0**
RL: ARU (Analytical role, unclassified); ANST (Analytical study)
(peptide stds. for quantification of human serum glycoproteins using mass spectrometry)

RN 870165-03-0 HCAPLUS
CN L-Valine, L-methionyl-L-alanyl-L-seryl-L-asparaginyl-L-valyl-L-threonyl-L-asparaginyl-L-lysyl-L-methionyl-L-α-aspartyl-L-prolyl-L-histidyl-L-seryl-L-methionyl-L-asparaginyl-L-seryl-L-arginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



PAGE 2-B



L22 ANSWER 4 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:303191 HCAPLUS
DN 142:341966
TI Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases
IN Schultz, Clyde L.
PA USA
SO U.S. Pat. Appl. Publ., 7 pp., Cont.-in-part of U.S. Ser. No. 821,718.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US2005074497	A1	20050407	2004US-0971997	20041022
US2005208102	A1	20050922	2004US-0821718	20040409
US2005255144	A1	20051117	2005US-0102454	20050409
WO2005110473	A2	20051124	2005WO-US12185	20050409

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI 2003US-461354P	P	20030409	
2004US-0821718	A2	20040409	
2004US-0971997	A2	20041022	

AB This invention provides a polymeric drug delivery system including a hydrogel containing one or more drugs for the treatment of a posterior segment disease. Exemplary drugs are anti-angiogenesis compds. for the treatment of macular degeneration. Allowing passive transference of this drug from a dilute solution into the hydrogel produces the delivery system. The hydrogel, when placed in contact with the eye, delivers the drug. The delivery of the drug is sustained over an extended period of time, which is of particular utility in the eye, which is periodically flushed with tears. This sustained delivery accelerates the treatment process while avoiding potential damaging effects of localized delivery of high concns. of compds., e.g., from eye drops.
IT **262438-43-7**, ATN-161
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)
(hydrogels containing drugs for treatment of eye diseases in posterior segment)

RN 262438-43-7 HCAPLUS
CN L-Aspartamide, 1-acetyl-L-prolyl-L-histidyl-L-seryl-L-cysteinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L22 ANSWER 5 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:631705 HCAPLUS
DN 138:297158
TI Suppression of Tumor Recurrence and Metastasis by a Combination of the PHSCN Sequence and the Antiangiogenic Compound Tetrathiomolybdate in Prostate Carcinoma
AU van Golen, Kenneth L.; Bao, Liwei; Brewer, George J.; Pienta, Kenneth J.; Kamradt, Jeffrey M.; Livant, Donna L.; Merajver, Sofia D.
CS Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, 48109-0948, USA
SO Neoplasia (New York, NY, United States) (2002), 4(5), 373-379
CODEN: NEOPFL; ISSN: 1522-8002
PB Nature Publishing Group
DT Journal
LA English
AB Plasma fibronectin-mediated invasion of human DU145 prostate cancer cell line was efficaciously inhibited in a rat tumor model by treatment with Ac-PHSCN-NH2 peptide. Invasion of DU145 cells was stimulated by the PHSRN sequence of plasma fibronectin. However, PHSCN acts as a competitive inhibitor of PHSRN-mediated invasion. In the current study, we determined whether PHSCN could inhibit the recurrence and metastasis of DU145 tumors after excision of the primary tumor in an athymic nude mouse model. We demonstrated that mice treated thrice weekly with i.v. Ac-PHSCN-NH2 peptide survived tumor-free for more than 30 wk post-primary tumor excision, whereas their untreated counterparts succumbed to recurrence and/or metastatic disease in significantly less time. Because of the universal requirement for angiogenesis in solid tumor growth, we tested the efficacy of copper deficiency induced by tetrathiomolybdate (TM) to retard tumor growth in the Dunning prostate cancer model. Significant reduction in size of the primary tumor was observed in mice rendered copper deficient. We sought to reduce tumor growth at the primary and metastatic sites by combining the anti-invasion Ac-PHSCN-NH2 peptide with TM. Improved survival, fewer metastatic lesions, and excellent tolerability were observed with the combination therapy.
IT **262438-43-7**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(suppression of tumor recurrence and metastasis by a combination of PHSCN sequence and the antiangiogenic compound tetrathiomolybdate in prostate carcinoma)

RN 262438-43-7 HCAPLUS
CN L-Aspartamide, 1-acetyl-L-prolyl-L-histidyl-L-seryl-L-cysteinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Allen, M	1998	29	311	Hum Pathol	MEDLINE
American Cancer Society	2002			Cancer Facts and Fig	
Livant, D	1995	55	5085	Cancer Res	HCAPLUS
Livant, D	2000	60	309	Cancer Res	HCAPLUS
Mosher, D	1984	35	561	Annu Rev Med	HCAPLUS
Nozue, M	2001	8	1247	Oncol Rep	MEDLINE
Partin, A	2001	58	843	Urology	MEDLINE
Rokhlin, O	1995	26	205	Prostate	HCAPLUS
Romanov, V	1999	39	108	Prostate	HCAPLUS
Schroder, J	1998	45	1807	Hepatogastroenterolo	MEDLINE
Smith, D	1999	26	323	Urol Clin North Am	MEDLINE
Trikha, M	1996	56	5071	Cancer Res	HCAPLUS
Uchiyama, A	1999	81	721	Br J Cancer	MEDLINE
van Golen, K	1996	14	95	Clin Exp Metastasis	HCAPLUS
Webber, M	1995	1	1089	Clin Cancer Res	MEDLINE
Witkowski, C	1993	119	637	J Cancer Res Clin On	HCAPLUS
Zheng, D	1999	59	1655	Cancer Res	HCAPLUS

L22 ANSWER 6 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:555761 HCAPLUS
DN 137:121939
TI Compositions and methods for the use of fibronectin fragments in the diagnosis of cancer
IN Livant, Donna
PA The Regents of the University of Michigan, USA
SO PCT Int. Appl., 77 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO2002057786	A2	20020725	2002WO-US01189	20020115
	WO2002057786	A3	20031211		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA---2435320	AA	20020725	2002CA-2435320	20020115
	EP---1388013	A2	20040211	2002EP-0713418	20020115
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				

IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
PRAI 2001US-0765496 A 20010118
2002WO-US01189 W 20020115
OS MARPAT 137:121939
AB The present invention concerns the detection tumors in vivo, the imaging of tumors in vivo, and the imaging of cancerous tissue in pathol. samples. In particular the present invention incorporates the use of fibronectin fragments into these same detection and imaging methods.
IT **252230-05-0 262438-43-7 443305-20-2**
443305-23-5
RL: ARG (Analytical reagent use); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(compns. and methods for use of fibronectin fragments in diagnosis of cancer)
RN 252230-05-0 HCAPLUS
CN L-Asparagine, L-prolyl-L-histidyl-L-seryl-L-homocysteinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 262438-43-7 HCAPLUS
CN L-Aspartamide, 1-acetyl-L-prolyl-L-histidyl-L-seryl-L-cysteinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 443305-20-2 HCAPLUS
CN L-Asparagine, L-prolyl-L-histidyl-L-seryl-D-cysteinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 443305-23-5 HCAPLUS
CN L-Aspartamide, 1-acetyl-L-prolyl-L-histidyl-L-seryl-D-cysteinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **252229-85-9P**
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(compns. and methods for use of fibronectin fragments in diagnosis of cancer)
RN 252229-85-9 HCAPLUS
CN L-Asparagine, L-prolyl-L-histidyl-L-seryl-L-cysteinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L22 ANSWER 7 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2000:824291 HCAPLUS
DN 134:21425
TI Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
IN Bridon, Dominique P.; Ezrin, Alan M.; Milner, Peter G.; Holmes, Darren L.; Thibaudeau, Karen

PA Conjuchem, Inc., Can.
SO PCT Int. Appl., 733 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO2000069900	A2	20001123	2000WO-US13576	20000517
	WO2000069900	A3	20010215		
	WO2000069900	C2	20020704		
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA---2373252	AA	20001123	2000CA-2373252	20000517
	CA---2373680	AA	20001123	2000CA-2373680	20000517
	CA---2499211	AA	20001123	2000CA-2499211	20000517
	CA---2501421	AA	20001123	2000CA-2501421	20000517
	CA---2505617	AA	20001123	2000CA-2505617	20000517
	WO2000070665	A2	20001123	2000WO-IB00763	20000517
	WO2000070665	A3	20010419		
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP---1105409	A2	20010613	2000EP-0936023	20000517
	EP---1105409	B1	20060301		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY				
	EP---1171582	A2	20020116	2000EP-0929748	20000517
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	EP---1264840	A1	20021211	2002EP-0014617	20000517
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
	JP2003500341	T2	20030107	2000JP-0619018	20000517
	JP2003508350	T2	20030304	2000JP-0618316	20000517
	AU----765753	B2	20030925	2000AU-0051393	20000517
	EP---1591453	A1	20051102	2005EP-0105384	20000517
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
	CN---1698881	A	20051123	CN 2005-10005990	20000517
	EP---1598365	A1	20051123	2005EP-0105387	20000517
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
	EP---1623994	A2	20060208	2005EP-0108328	20000517
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
	AT----318835	E	20060315	2000AT-0936023	20000517
	ES---2257298	T3	20060801	2000ES-0936023	20000517
	US---6849714	B1	20050201	2000US-0623548	20000905
	US---6514500	B1	20030204	2000US-0657332	20000907
	US---7090851	B1	20060815	2000US-0657336	20000907
	ZA2001006676	A	20020719	2001ZA-0006676	20010814
	ZA2001009110	A	20020613	2001ZA-0009110	20011105
	US2003108567	A1	20030612	2002US-0287892	20021104

	US---6821949	B2	20041123		
	US2003108568	A1	20030612	2002US-0288340	20021104
	US---6887849	B2	20050503		
	US2004127398	A1	20040701	2003US-0722733	20031125
	US2004138100	A1	20040715	2003US-0723099	20031125
	US2005176641	A1	20050811	2005US-0040810	20050121
	US2005176643	A1	20050811	2005US-0067556	20050225
	JP2005263807	A2	20050929	2005JP-0115175	20050412
	JP2005239736	A2	20050908	2005JP-0140407	20050512
	JP2005255689	A2	20050922	2005JP-0151458	20050524
	US2006009377	A1	20060112	2005US-0170967	20050629
	US2006058235	A1	20060316	2005US-0215967	20050830
	JP2006151986	A2	20060615	2005JP-0361126	20051214
	US2006135426	A1	20060622	2005US-0304446	20051214
	US2006135428	A1	20060622	2006US-0350703	20060208
PRAI	1999US-134406P	P	19990517		
	1999US-153406P	P	19990910		
	1999US-159783P	P	19991015		
	2000CA-2363712	A3	20000517		
	2000CA-2373680	A3	20000517		
	2000CN-0807671	A3	20000517		
	2000EP-0932570	A3	20000517		
	2000EP-0936023	A3	20000517		
	2000JP-0618316	A3	20000517		
	2000JP-0618327	A3	20000517		
	2000WO-IB00763	W	20000517		
	2000WO-US13576	W	20000517		
	2000US-0623543	A1	20000905		
	2000US-0623548	A1	20000905		
	2000US-0657276	A2	20000907		
	2000US-0657332	A3	20000907		
	2000US-0657431	A1	20000907		
	2002US-400199P	P	20020731		
	2002US-400413P	P	20020731		
	2002US-0288340	A1	20021104		
	2003WO-CA01097	W	20030729		
	2003US-0471348	B1	20030908		
	2003US-0722733	A1	20031125		
	2005US-0040810	A2	20050121		
	2005US-0170967	A1	20050629		
	2005US-0215967	A1	20050830		

AB A method for protecting a peptide from peptidase activity in vivo, the peptide being composed of between 2 and 50 amino acids and having a C-terminus and an N-terminus and a C-terminus amino acid and an N-terminus amino acid is described. In the first step of the method, the peptide is modified by attaching a reactive group to the C-terminus amino acid, to the N-terminus amino acid, or to an amino acid located between the N-terminus and the C-terminus, such that the modified peptide is capable of forming a covalent bond in vivo with a reactive functionality on a blood component. The solid phase peptide synthesis of a number of derivs. with 3-maleimidopropionic acid (3-MPA) is described. In the next step, a covalent bond is formed between the reactive group and a reactive functionality on a blood component to form a peptide-blood component conjugate, thereby protecting said peptide from peptidase activity. The final step of the method involves the analyzing of the stability of the peptide-blood component conjugate to assess the protection of the peptide from peptidase activity. Thus, the percentage of a K5 kringle peptide (Pro-Arg-Lys-Leu-Tyr-Asp-Lys-NH2) conjugated to human serum albumin via MPA remained relatively constant through a 24-h plasma assay in contrast to unmodified K5 which decreased to 9% of the original amount of K5 in only 4 h in plasma.

IT **252229-85-9**
RL: PRP (Properties)
(unclaimed sequence; protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components)

RN 252229-85-9 HCAPLUS

CN L-Asparagine, L-prolyl-L-histidyl-L-seryl-L-cysteinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L22 ANSWER 8 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2000:102218 HCAPLUS
DN 132:245978
TI Anti-invasive, antitumorigenic, and antimetastatic activities of the PHSCN sequence in prostate carcinoma
AU Livant, Donna L.; Brabec, R. Kaye; Pienta, Kenneth J.; Allen, David L.; Kurachi, Kotoku; Markwart, Sonja; Upadhyaya, Ameet
CS Department of Cell and Development Biology, University of Michigan Medical School, Ann Arbor, MI, 48109-0616, USA
SO Cancer Research (2000), 60(2), 309-320
CODEN: CNREA8; ISSN: 0008-5472
PB AACR Subscription Office
DT Journal
LA English
AB Using naturally serum-free SU-ECM basement membranes as invasion substrates showed that plasma fibronectin was necessary to stimulate invasion by DU 145 human and metastatic MATLyLu (MLL) rat prostate carcinoma cells. This activity mapped to the PHSRN sequence, which induced invasion through α5β1 integrin. PHSCN, a competitive inhibitor, blocked both PHSRN- and serum-induced invasion. Acetylated, amidated PHSCN (Ac-PHSCN-NH2) was 30-fold more potent; however, Ac-HSPNC-NH2 was inactive. Rats receiving injections s.c. with 100,000 MLL cells were treated systemically by i.v. injection three times weekly with 1 mg of either Ac-PHSCN-NH2 or Ac-HSPNC-NH2 beginning 24 h later, three times weekly with 1 mg of Ac-PHSCN-NH2 beginning only after surgery to remove large (2 cm) MLL tumors, or were left untreated. MLL tumors grew rapidly in Ac-HSPNC-NH2-treated and in untreated rats. MLL tumor growth in rats treated with Ac-PHSCN-NH2 beginning 1 day after MLL cell injection was reduced by 99.9% during the first 16 days of treatment, although subsequent tumor growth occurred. MLL tumor cryosections immunostained with anti-PECAM-1 showed that Ac-PHSCN-NH2 inhibited neovascularization by 12-fold during this time. Whether initiated after MLL cell injection or only after MLL tumor removal, Ac-PHSCN-NH2 treatment reduced the nos. of MLL lung colonies and micrometastases by 40- to > 100-fold, whereas Ac-HSPNC-NH2 was inactive. Thus, Ac-PHSCN-NH2 may be a potent antitumorigenic and antimetastatic agent for postsurgical use prior to extensive metastasis.
IT **262438-43-7**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(anti-invasive, antitumorigenic, and antimetastatic activities of the PHSCN sequence in prostate carcinoma)
RN 262438-43-7 HCAPLUS
CN L-Aspartamide, 1-acetyl-L-prolyl-L-histidyl-L-seryl-L-cysteinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Akiyama, S	1995	14	173	Cancer Metastasis Re	HCAPLUS
Akiyama, S	1985	260	4492	J Biol Chem	HCAPLUS
Amemiya, S	1989	31	131	Dev Growth Differ	
Aota, S	1994	269	24756	J Biol Chem	HCAPLUS
Atherton, E	1989			Solid Phase Peptide	
Burnette, W	1981	112	195	Anal Biochem	HCAPLUS
Carter, H	1988		1	A Multidisciplinary	
Clark, R	1996		12	The Molecular and Ce	
de Souza, P	1997	75	1593	Br J Cancer	HCAPLUS
Doherty, D	1990	86	1065	J Clin Invest	HCAPLUS
Dunning, W	1963	12	351	Monogr Natl Cancer I	MEDLINE
Elstein, K	1994	211	322	Exp Cell Res	HCAPLUS
Flaris, N	1993	7	34	GLIA	MEDLINE
Foulkes, E	1991		171	Metallothionein in B	HCAPLUS
Fournier, G	1996	30	32	Eur Urol	
Hayman, E	1979	83	255	J Cell Biol	HCAPLUS
Hayman, E	1982	82	803	Methods Enzymol	
Huhtala, P	1995	129	867	J Cell Biol	HCAPLUS
Humason, G	1972		34	Animal Tissue Techni	
Humphries, M	1986	233	467	Science (Washington	HCAPLUS
Isaacs, J	1986	9	261	Prostate	MEDLINE
Iwamoto, Y	1987	238	1132	Science (Washington	HCAPLUS
Johansson, S	1998	77	1213	Br J Cancer	HCAPLUS
Jungwirth, A	1997	75	1585	Br J Cancer	HCAPLUS
Kim, J	1998	94	353	Cell	HCAPLUS
Lafarga, M	1997	75	137	J Neurosci Methods	HCAPLUS
Litvinovich, S	1995	248	611	J Mol Biol	HCAPLUS
Livant, D	1995	55	5085	Cancer Res	HCAPLUS
Male, D	1995	84	453	Immunology	HCAPLUS
Mant, C	1997	289	426	Methods Enzymol	HCAPLUS
Mogford, J	1997	100	1647	J Clin Investig	HCAPLUS
Mosher, D	1984	35	561	Annu Rev Med	HCAPLUS
Mould, A	1997	272	17283	J Biol Chem	HCAPLUS
Newman, P	1997	100	S25	J Clin Invest	
Peehl, D	1992		159	Culture of Epithelia	
Pienta, K	1995	87	348	J Natl Cancer Inst	HCAPLUS
Pienta, K	1992	20	233	Prostate	HCAPLUS
Pinski, J	1994	54	169	Cancer Res	HCAPLUS
Pinski, J	1993	23	165	Prostate	HCAPLUS
Postlethwaite, A	1976	144	1188	J Exp Med	HCAPLUS
Postlethwaite, A	1981	153	494	J Exp Med	HCAPLUS
Raghaven, D	1988	15	371	Semin Oncol	
Reed, G	1986		313	Manganese in Metabol	HCAPLUS
Roklin, O	1995	26	205	Prostate	
Rossino, P	1990	189	100	Exp Cell Res	HCAPLUS
Saiki, I	1990	81	660	Jpn J Cancer Res	HCAPLUS
Schulze, H	1987	243A	1	Prostate Cancer Part	MEDLINE

Silverberg, E	1988	38	107	CA Cancer J Clin	
Srialovic, G	1990	127	3052	Endocrinology	
Stone, K	1978	21	274	Int J Cancer	MEDLINE
Templeton, N	1990	50	5431	Cancer Res	HCAPLUS
Tomaselli, K	1988	107	1241	J Cell Biol	HCAPLUS
Von Eschenbach, A	1997	47	261	CA Cancer J Clin	MEDLINE
Vukanovic, J	1995	55	1499	Cancer Res	HCAPLUS
Wayner, E	1988	107	1881	J Cell Biol	HCAPLUS
Wiltbank, M	1990	42	139	Biol Reprod	MEDLINE
Witkowski, C	1993	119	637	Cancer Res Clin Onco	HCAPLUS
Zar, J	1984		138	Biostatistical Analy	

L22 ANSWER 9 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 1999:794362 HCAPLUS
DN 132:30820
TI Anticancer compounds and methods
IN Livant, Donna L.
PA Regents of the University of Michigan, USA
SO U.S., 53 pp., Cont.-in-part of U. S. 5,840,514.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US---6001965	A	19991214	1997US-0915189	19970820
	US---5840514	A	19981124	1996US-0754322	19961121
	CA---2264570	AA	19980528	1997CA-2264570	19971120
	WO---9822617	A1	19980528	1997WO-US21674	19971120
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
	RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	EP----928340	A1	19990714	1997EP-0949632	19971120
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	US---5989850	A	19991123	1998US-0140047	19980826
	US---6472369	B1	20021029	1999US-0373694	19990813
	AU----765126	B2	20030911	2001AU-0051984	20010618
	US2003083264	A1	20030501	2002US-0237850	20020909
	AU2003268832	A1	20040122	2003AU-0268832	20031211
PRAI	1996US-0754322	A2	19961121		
	1997US-0915189	A	19970820		
	1997WO-US21674	W	19971120		
	1999US-0373694	A3	19990813		
	2001AU-0051984	A3	20010618		

OS MARPAT 132:30820
AB The testing of tumor cells, including human tumors capable of metastases, in assays employing fibronectin-depleted substrates is described. Ex vivo induction of cells, including biopsied human cells, is performed with invasion-inducing agents. Addnl., anti-cancer chemotherapeutics are described. Specifically, chemotherapeutic agents which have anti-metastatic and anti-growth properties are described.
IT **252229-85-9 252230-05-0**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antitumor peptides and inhibition of metastasis)
RN 252229-85-9 HCAPLUS
CN L-Asparagine, L-prolyl-L-histidyl-L-seryl-L-cysteinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252230-05-0 HCAPLUS
CN L-Asparagine, L-prolyl-L-histidyl-L-seryl-L-homocysteinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Anon	1995			WO---9524471	HCAPLUS
Anon	1996			WO---9612823	HCAPLUS
Aversa	1996			US---5576423	HCAPLUS
Bischoff	1996			US---5539085	HCAPLUS
Bohn	1984			US---4424279	HCAPLUS
Bresalier	1995	55	2476	Cancer Research	HCAPLUS
Burke	1992			US---5169862	HCAPLUS
Calabresi, P			1209	Goodman and Gilman T	
Doersen	1993			US---5264358	
Douillard	1981	II		Compendium of Immuno	
Eldred	1994	37	3882	J Med Chem	HCAPLUS
Gaeta	1996			US---5559103	HCAPLUS
Gartner, T		260	11891	The Journal of Biolo	HCAPLUS
Gerlach, J	1986	5	25	Cancer Surveys	MEDLINE
Ginsberg	1996			US---5523209	HCAPLUS
Ginsburg	1996			US---5492890	HCAPLUS
Goldie, J	1984	44	3643	Cancer Research	HCAPLUS
Hashino	1992			US---5136023	HCAPLUS
Isoai	1996			US---5548062	HCAPLUS
Kitaguchi	1995			US---5436221	HCAPLUS
Kohler, G	1976	6	511	European Journal of	MEDLINE
Kohler, G	1975	256	495	Nature	MEDLINE
Ku	1995	38	9	J Med Chem	HCAPLUS
Lipman, D	1985	227	1435	Science	HCAPLUS

Livant, D	1995	55	5085	Cancer Research	HCAPLUS
Lobl	1993			US---5192746	HCAPLUS
Mennen	1977			US---4018653	HCAPLUS
Nicholson, N	1995	62	567	Thrombosis Research	
Nomizu, M	1993	53	3459	Cancer Research	HCAPLUS
Pearson, W	1988	85	2444	Proc Natl Acad Sci (	HCAPLUS
Reading, C	1982	53	261	Journal of Immunolog	MEDLINE
Saiki, I	1989	49	3815	Cancer Research	HCAPLUS
Schuurs	1977			US---4016043	HCAPLUS
Shashoua	1991			US---5051448	HCAPLUS
Stone, K	1978	21	274	Int J Cancer	MEDLINE
Wenger, R		73	1498	Blood	HCAPLUS

=> b uspatall
FILE 'USPATFULL' ENTERED AT 16:54:26 ON 19 OCT 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 16:54:26 ON 19 OCT 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

=> d bib abs hitrn fhitstr l24 5-6

L24 ANSWER 5 OF 7 USPATFULL on STN
AN 2005:24260 USPATFULL
TI Peptides which target tumor and endothelial cells, compositions and uses thereof
IN Ternansky, Robert J., San Diego, CA, UNITED STATES
Allan, Amy L., Encinitas, CA, UNITED STATES
Gladstone, Patricia L., San Diego, CA, UNITED STATES
Yoon, Won Hyung, San Diego, CA, UNITED STATES
Parry, Graham, San Diego, CA, UNITED STATES
Donate, Fernando, San Diego, CA, UNITED STATES
Mazar, Andrew, San Diego, CA, UNITED STATES
PI US2005020810 A1 20050127
AI 2003US-0722843 A1 20031125 (10)
PRAI 2002US-429174P 20021125 (60)
2003US-475539P 20030602 (60)
DT Utility
FS APPLICATION
LREP Sunil K. Singh, Dorsey & Whitney LLP, Intellectual Property Department, Four Embarcadero Center, Suite 3400, San Francisco, CA, 94111-4187
CLMN Number of Claims: 74
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3884
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates generally to peptide analogs of Ac--PHSCN--NH.sub.2 which target tumor and endothelial cells and have anti-tumor, anti-angiogenic and anti-metasastic activity, methods of making these peptides, compositions thereof and methods of using these peptides and pharmaceutical compositions thereof to treat, prevent and detect diseases characterized by tumor growth, metastasis and angiogenesis. The peptide analogs may serve, inter alia, as carriers of radioactivity, PET-active compounds, toxins, fluorescent molecules and PEG molecules.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **701200-82-0P 701201-01-6P**
(peptide inhibitors of angiogenesis, cell migration, cell invasion and cell proliferation, preparation, and compns. and therapeutic uses)
IT **701200-81-9P 701200-83-1P 701200-84-2P**
701200-88-6P 701200-90-0P 701200-91-1P
701200-92-2P 701200-93-3P 701200-99-9P
701201-00-5P 701201-02-7P 701201-03-8P
701201-04-9P 701201-05-0P 701201-06-1P

701201-07-2P 701201-08-3P 701201-09-4P
701201-10-7P 701201-11-8P 701201-12-9P
701201-13-0P 701201-14-1P 701201-15-2P
701201-16-3P 701201-17-4P 701201-18-5P
701201-19-6P 701201-20-9P 701201-21-0P
701201-24-3P 701201-25-4P
(peptide inhibitors of angiogenesis, cell migration, cell invasion and cell proliferation, preparation, and compns. and therapeutic uses)

IT 262438-43-7
(peptide inhibitors of angiogenesis, cell migration, cell invasion and cell proliferation, preparation, and compns. and therapeutic uses)

IT 701200-82-0P
(peptide inhibitors of angiogenesis, cell migration, cell invasion and cell proliferation, preparation, and compns. and therapeutic uses)

RN 701200-82-0 USPATFULL

CN L-Aspartamide, 1-acetyl-L-prolyl-L-histidyl-L-seryl-S-[(4-methylphenyl)methyl]-L-cysteinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L24 ANSWER 6 OF 7 USPATFULL on STN

AN 2004:209805 USPATFULL

TI Peptides which inhibit angiogenesis, cell migration, cell invasion and cell proliferation, compositions and uses thereof

IN Allan, Amy L., Encinitas, CA, UNITED STATES
Donate, Fernando, San Diego, CA, UNITED STATES
Hopkins, Stephanie A., Poway, CA, UNITED STATES
Gladstone, Patricia L., San Diego, CA, UNITED STATES
Mazar, Andrew, San Diego, CA, UNITED STATES
O'Hare, Sean M., San Diego, CA, UNITED STATES
Parry, Graham, San Diego, CA, UNITED STATES
Plunkett, Marian, San Diego, CA, UNITED STATES
Ternansky, Robert J., San Diego, CA, UNITED STATES
Yoon, Won Hyung, San Diego, CA, UNITED STATES

PI US2004162239 A1 20040819

AI 2003US-0723144 A1 20031125 (10)

PRAI 2002US-429174P 20021125 (60)
2003US-475539P 20030602 (60)

DT Utility

FS APPLICATION

LREP COOLEY GODWARD, LLP, 3000 EL CAMINO REAL, 5 PALO ALTO SQUARE, PALO ALTO, CA, 94306

CLMN Number of Claims: 65

ECL Exemplary Claim: 1

DRWN 5 Drawing Page(s)

LN.CNT 3373

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates generally to peptides, which inhibit angiogenesis, cell migration, cell invasion and cell proliferation, methods of making peptides, which inhibit angiogenesis, cell migration, cell invasion and cell proliferation, pharmaceutical compositions of these peptides and methods of using these peptides and pharmaceutical compositions of these peptides to treat diseases associated with aberrant vascularization.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **701200-82-0P 701201-01-6P**
(peptide inhibitors of angiogenesis, cell migration, cell invasion and cell proliferation, preparation, and compns. and therapeutic uses)
IT **701200-81-9P 701200-83-1P 701200-84-2P**
701200-88-6P 701200-90-0P 701200-91-1P
701200-92-2P 701200-93-3P 701200-99-9P
701201-00-5P 701201-02-7P 701201-03-8P
701201-04-9P 701201-05-0P 701201-06-1P
701201-07-2P 701201-08-3P 701201-09-4P
701201-10-7P 701201-11-8P 701201-12-9P
701201-13-0P 701201-14-1P 701201-15-2P
701201-16-3P 701201-17-4P 701201-18-5P
701201-19-6P 701201-20-9P 701201-21-0P
701201-24-3P 701201-25-4P
(peptide inhibitors of angiogenesis, cell migration, cell invasion and cell proliferation, preparation, and compns. and therapeutic uses)
IT **262438-43-7**
(peptide inhibitors of angiogenesis, cell migration, cell invasion and cell proliferation, preparation, and compns. and therapeutic uses)
IT **701200-82-0P**
(peptide inhibitors of angiogenesis, cell migration, cell invasion and cell proliferation, preparation, and compns. and therapeutic uses)
RN 701200-82-0 USPATFULL
CN L-Aspartamide, 1-acetyl-L-prolyl-L-histidyl-L-seryl-S-[(4-methylphenyl)methyl]-L-cysteinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> d bib abs hitstr l24 1-4 7

L24 ANSWER 1 OF 7 USPATFULL on STN
AN 2006:167022 USPATFULL
TI Compositions and methods for quantification of serum glycoproteins
IN Aebersold, Rudolf H., Zurich, SWITZERLAND
Zhang, Hui, Seattle, WA, UNITED STATES

PI US2006141528 A1 20060629
AI 2005US-0134871 A1 20050520 (11)
PRAI 2004US-573593P 20040521 (60)
DT Utility
FS APPLICATION
LREP MCDERMOTT, WILL & EMERY, 4370 LA JOLLA VILLAGE DRIVE, SUITE 700, SAN DIEGO, CA, 92122, US
CLMN Number of Claims: 50
ECL Exemplary Claim: 1
DRWN 22 Drawing Page(s)
LN.CNT 9380
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides compositions and methods for identifying and/or quantifying glycopolypeptides from human serum or plasma. The compositions and methods include a plurality of standard peptides containing glycosylation sites determined for human serum/plasma proteins.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **870165-03-0**
(peptide stds. for for quantification of human serum glycoproteins using mass spectrometry)
RN 870165-03-0 USPATFULL
CN L-Valine, L-methionyl-L-alanyl-L-seryl-L-asparaginyl-L-valyl-L-threonyl-L-asparaginyl-L-lysyl-L-methionyl-L-α-aspartyl-L-prolyl-L-histidyl-L-seryl-L-methionyl-L-asparaginyl-L-seryl-L-arginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



PAGE 2-B



L24 ANSWER 2 OF 7 USPATFULL on STN
AN 2006:92408 USPATFULL
TI Anticancer compounds and methods
IN Livant, Donna, Ann Arbor, MI, UNITED STATES
PA The Regents of the University of Michigan, Ann Arbor, MI, UNITED STATES (U.S. corporation)
PI US2006078535 A1 20060413
AI 2004US-0964093 A1 20041013 (10)
DT Utility
FS APPLICATION
LREP Peter G. Carroll, MEDLEN & CARROLL, LLP, Suite 350, 101 Howard Street, San Francisco, CA, 94105, US
CLMN Number of Claims: 18
ECL Exemplary Claim: 1
DRWN 40 Drawing Page(s)
LN.CNT 3134
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The testing of tumor cells, including human tumors capable of metastases, in assays employing fibronectin-depleted substrates is described. Ex vivo induction of cells, including biopsied human cells, is performed with invasion-inducing agents. Additionally, anti-cancer chemotherapeutics are described. Specifically, chemotherapeutic agents

which have anti-metastatic and anti-growth properties are described including non-peptide compositions of matter.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **252229-85-9D**, conjugates with dendrimers and chemotherapeutic agents
(anticancer compds. and methods using dendrimers and peptides and attached chemotherapeutic agents)

RN 252229-85-9 USPATFULL

CN L-Asparagine, L-prolyl-L-histidyl-L-seryl-L-cysteinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **252230-05-0**
(metastasis inhibition by; anticancer compds. and methods using dendrimers and peptides and attached chemotherapeutic agents)

RN 252230-05-0 USPATFULL

CN L-Asparagine, L-prolyl-L-histidyl-L-seryl-L-homocysteinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **252229-85-9 883198-05-8 883198-06-9**
(unclaimed sequence; anticancer compds. and methods)

RN 252229-85-9 USPATFULL

CN L-Asparagine, L-prolyl-L-histidyl-L-seryl-L-cysteinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 883198-05-8 USPATFULL
CN L-Lysine, L-prolyl-L-histidyl-L-seryl-L-cysteinyl-L-asparaginylglycylglycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 883198-06-9 USPATFULL
CN Glycine, L-prolyl-L-histidyl-L-seryl-L-cysteinyl-L-asparaginylglycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L24 ANSWER 3 OF 7 USPATFULL on STN
AN 2005:240102 USPATFULL
TI Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases
IN Schultz, Clyde L., Ponte Vedra, FL, UNITED STATES
PI US2005208102 A1 20050922
AI 2004US-0821718 A1 20040409 (10)
PRAI 2003US-461354P 20030409 (60)
DT Utility
FS APPLICATION
LREP FINCH IP LLC, P.O. BOX 1358, CONCORD, NH, 03302, US
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 502
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention provides a polymeric drug delivery system including a hydrogel containing one or more drugs for the treatment of a posterior segment disease. Allowing passive transference of this drug from a dilute solution into the hydrogel produces the delivery system. The hydrogel, when placed in contact with the eye, delivers the drug. The delivery of the drug is sustained over an extended period of time, which is of particular utility in the eye, which is periodically flushed with tears. This sustained delivery accelerates the treatment process while avoiding potential damaging effects of localized delivery of high concentrations of compounds, e.g., from eye drops.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **262438-43-7**, ATN-161
(hydrogels containing drugs for treatment of eye diseases in posterior segment)
RN 262438-43-7 USPATFULL
CN L-Aspartamide, 1-acetyl-L-prolyl-L-histidyl-L-seryl-L-cysteinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L24 ANSWER 4 OF 7 USPATFULL on STN
AN 2005:87035 USPATFULL
TI Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases
IN Schultz, Clyde L., Ponte Vedra, FL, UNITED STATES
PI US2005074497 A1 20050407
AI 2004US-0971997 A1 20041022 (10)
RLI Continuation-in-part of Ser. No. 2004US-0821718, filed on 9 Apr 2004, PENDING
PRAI 2003US-461354P 20030409 (60)
DT Utility
FS APPLICATION
LREP CLARK & ELBING LLP, 101 FEDERAL STREET, BOSTON, MA, 02110
CLMN Number of Claims: 27
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 582
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention provides a polymeric drug delivery system including a hydrogel containing one or more drugs for the treatment of a posterior segment disease. Exemplary drugs are anti-angiogenesis compounds for the treatment of macular degeneration. Allowing passive transference of this drug from a dilute solution into the hydrogel produces the delivery system. The hydrogel, when placed in contact with the eye, delivers the drug. The delivery of the drug is sustained over an extended period of time, which is of particular utility in the eye, which is periodically flushed with tears. This sustained delivery accelerates the treatment process while avoiding potential damaging effects of localized delivery of high concentrations of compounds, e.g., from eye drops.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **262438-43-7**, ATN-161
(hydrogels containing drugs for treatment of eye diseases in posterior segment)
RN 262438-43-7 USPATFULL
CN L-Aspartamide, 1-acetyl-L-prolyl-L-histidyl-L-seryl-L-cysteinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L24 ANSWER 7 OF 7 USPATFULL on STN
AN 1999:163820 USPATFULL
TI Anticancer compounds and methods
IN Livant, Donna L., Ann Arbor, MI, United States
PA The Regents of the University of Michigan, Ann Arbor, MI, United States (U.S. corporation)
PI US---6001965 19991214
AI 1997US-0915189 19970820 (8)
RLI Continuation-in-part of Ser. No. 1996US-0754322, filed on 21 Nov 1996, now patented, Pat. No. US---5840514, issued on 24 Nov 1998
DT Utility
FS Granted
EXNAM Primary Examiner: Woodward, Michael P.; Assistant Examiner: Borin,

Michael
LREP Medlen & Carroll, LLP
CLMN Number of Claims: 5
ECL Exemplary Claim: 1
DRWN 16 Drawing Figure(s); 15 Drawing Page(s)
LN.CNT 2294
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The testing of tumor cells, including human tumors capable of metastases, in assays employing fibronectin-depleted substrates is described. Ex vivo induction of cells, including biopsied human cells, is performed with invasion-inducing agents. Additionally, anti-cancer chemotherapeutics are described. Specifically, chemotherapeutic agents which have anti-metastatic and anti-growth properties are described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **252229-85-9 252230-05-0**
(antitumor peptides and inhibition of metastasis)
RN 252229-85-9 USPATFULL
CN L-Asparagine, L-prolyl-L-histidyl-L-seryl-L-cysteinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252230-05-0 USPATFULL
CN L-Asparagine, L-prolyl-L-histidyl-L-seryl-L-homocysteinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> d his

(FILE 'HOME' ENTERED AT 16:31:24 ON 19 OCT 2006)

FILE 'HCAPLUS' ENTERED AT 16:31:37 ON 19 OCT 2006

```
L1            3 US2005020810/PN OR (US2003-722843 OR US2002-429174# OR US2003-4

     FILE 'REGISTRY' ENTERED AT 16:33:25 ON 19 OCT 2006

     FILE 'HCAPLUS' ENTERED AT 16:33:25 ON 19 OCT 2006
L2              TRA L1 1- RN :      209 TERMS

     FILE 'REGISTRY' ENTERED AT 16:33:26 ON 19 OCT 2006
L3            209 SEA L2
L4                STR
L5              0 L4
L6            110 L4 FULL
                  SAV TEM L6 GAR843B1/A
L7             90 L6 AND L3
L8             20 L6 NOT L7

     FILE 'HCAPLUS' ENTERED AT 16:48:39 ON 19 OCT 2006
L9             14 L6
                  E TERNANSKY R/AU
L10            63 E4-9
                  E ALLAN A/AU
L11            36 E3,E11
                  E ALLAN AMY/AU
L12            10 E4-5
                  E GLADSTONE P/AU
L13            29 E3-7
                  E YOON W/AU
L14            16 E3,E6
                  E YOON WON/AU
L15            10 E13
                  E YOON WONHYUNG/AU
                  E PARRY G/AU
L16           182 E3-14
                  E PARRY GRAHAM
                  E PARRY GRAHAM/AU
L17            45 E3-5
                  E DONATE F/AU
L18            47 E3-7
                  E MAZAR A/AU
L19            85 E3-4,E7-9
L20            27 ATTENUON/CS,PA
L21             5 L9 AND L10-20
L22             9 L9 NOT L21

     FILE 'HCAOLD' ENTERED AT 16:51:54 ON 19 OCT 2006
L23             0 L6

     FILE 'USPATFULL, USPAT2' ENTERED AT 16:52:00 ON 19 OCT 2006
L24             7 L6

=>
```